SGLT2 Inhibitors Treatment Market Size & Share, By Application (Glucose Dissipation, Blood Transfusion); End-user (Hospitals, Clinics, Diagnostic Centres) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 3972
  • Published Date: Aug 25, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2023 - 2035

SGLT2 Inhibitors Treatment Market size is anticipated to reach USD 8 Billion by the end of 2035, growing at a CAGR of 9% during the forecast period, i.e., 2023 – 2035. In the year 2022, the industry size of SGLT2 inhibitor treatment was over USD 5.35 Billion. The increasing prevalence of diabetes has fuelled the demand for innovative products, advanced technologies, and personalized solutions.  According to the International Diabetes Federation, nearly 783 million adults will be living with diabetes by the end of 2045.

Government efforts to raise awareness of the disease to help in cure and diagnosis at an earlier stage are anticipated to elevate the market’s growth. Moreover, this is leading to growing awareness among people related to diabetes mellitus, and it’s treatment methods.


SGLT2 Inhibitors Treatment Market
Get more information on this report: Request Free Sample PDF


SGLT2 Inhibitors Treatment Market: Key Insights

Base Year

2022

Forecast Year

2023-2035

CAGR

~ 9%

Base Year Market Size (2022)

 ~ USD 5.35 Billion

Forecast Year Market Size (2035)

 ~ USD 8 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

SGLT2 Inhibitors Treatment Market: Growth Drivers and Challenges

Market-Growth-Drivers

Growth Drivers

  • Excessive Sugar Diet Leads to Incidences of Diabetic Patients- Diabetes is increased by consuming an excessive amount of sugar. In addition, the diabetes diagnostic market is growing at a fast rate due to advances in devices for diagnosis of diabetes such as portable glucometers. Glucometer is a little, portable device that measures the level of blood glucose for people with diabetes. By 2022, sugar consumption in the world is expected to reach around 176 million tons, and it is anticipated that by 2024 about 180.05 million tons will be consumed in the world's trade.
  • Growing Medical and R&D Activities- Pharmaceutical companies investing in the research and development of SGLT2 Inhibitors demonstrate their commitment to improving diabetic management and continued advancements in drug development. On average the Food and Drug Administration approved nearly 38 new drugs every year from 2010 to 2019.
  • Digital Health and Telemedicine- Leveraging technology, especially in the form of digital health platforms and telemedicine, can overcome geographical and linguistic barriers. However, with the recent emergence of digital therapeutics, helping to bring healthcare services online, this situation is changing to promote the adoption of telemedicine as it is convenient and boosts market growth.

Challenges

  • Economic limitations- Patients from the middle-low-income region might lack healthcare insurance or face financial constraints, limiting their ability to afford medical consultations or purchase expensive medications such as SGLT2 inhibitors. The middle low-income region often faces resource constraints, including inadequate healthcare infrastructure, which hinders the dissemination of knowledge about novel treatment like SGLT2.
  • Competition from Existing Diabetes Treatment Drug
  • Surging Risk of Amputations


SGLT2 Inhibitors Treatment Segmentation

Application (Glucose Dissipation, Blood Transfusion)

The glucose dissipation segment is estimated to hold 56% share of the global SGLT2 inhibitors treatment market during the forecasted timeframe. Due to the advancement in glucose dissipation, the SGLT2 treatment market is addressed the unbeatable growth of 8.6% over the years. In order to decrease high blood glucose, the SGLT2 inhibitors work by a new mechanism to reduce renal tubular glucose reabsorption and thus decrease blood glucose levels without inducing the release of insulin.

End Users (Hospitals, Clinics, Diagnostic Centers)

SGLT2 inhibitors treatment market from the diagnostic centers sector is predicted to show the largest share of 42 % by the end of 2035. The qualified healthcare professionals in diagnostic centers with a growing estimation of 14% per annum, such as endocrinologists or primary care physicians, often diagnose and prescribe SGLT2 inhibitors after thoroughly evaluating a patient's medical history, present health, and needs for diabetic management. Moreover, the rising investment in diagnostic services is further expected to boost the segment’s growth. For instance the National Health Service, spends more than USD 6 billion on more than 90 diagnostic services in a year.

Our in-depth analysis of the global market includes the following segments:

  Application

  • Glucose Dissipation
  •  Blood Transfusion

  End User

  • Hospitals
  • Clinics
  • Diagnostic Centres

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

SGLT2 Inhibitor Treatment Industry - Regional Synopsis

North America Market Analysis

North America is estimated to have the highest revenue share of 32% during the forecast period. With the increasing prevalence of obesity and lifestyle changes in the region, chronic diseases are growing on a yearly basis. Approximately 50 % of Americans suffer from at least one chronic disease every year. Additionally, it is predicted that the region's high healthcare spending will spur market expansion. According to data from the World Bank, the area of North America spent 16.415% of its total GDP on healthcare.

Asia Pacific Market Analysis

Asia Pacific region is expected to witness the fastest growth of 8.35% during the forecast period.  The factors such as rising disposable income, increasing social organization awareness, improving health care facilities, and more R&D activities are expected to drive the growth of the market in the Asia-pacific region.

Research Nester
SGLT2 Inhibitors Treatment Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the SGLT2 Inhibitors Treatment Landscape

top-features-companies
    • Novartis International AG
    • Company overview
    • Business strategy
    • Key product offerings
    • Financial performances
    • Key performance indicators
    • Risk analysis
    • Recent development
    • Regional presence
    • SWOT analysis
    • Boehringer Ingelheim GmbH
    • Janssen pharmaceuticals
    • GRUPO TECNIMEDE
    • Unichem Laboratories Ltd.
    • Edificio Bluepharma

In-the-news

In The News

  • Astellas Pharma Inc., announced that selective SGLT2 inhibitor Suglat Tablets 25mg and 50mg Ipragliflozin L-Proline, “Suglat Tablets”) became available for the indication of type 2 diabetes in the Japanese market today.
  • AstraZeneca’s Forxiga (dapagliflozin) was approved in China to reduce the risk of cardiovascular (CV) death and hospitalization for heart failure in adults with heart failure (NYHA class II-IV) with reduced ejection fraction (HFrEF).

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 3972
  • Published Date: Aug 25, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Growing Concern for the Prevalence of diabetes mellitus is estimated to boost the SGLT2 inhibitor treatment market.

The market size of SGLT2 inhibitors treatment market is anticipated to attain a CAGR of 9% over the forecast period, i.e., 2023 – 2035.

The major players in the market are Novartis International AG, Boehringer Ingelheim GmbH, Janssen pharmaceutical, GRUPO TECNIMEDE, Unichem laboratories ltd, Edificio blue pharma, AstraZeneca Pharmaceuticals LP, Eli Lily and company, the mercy group, Pfizer Inc.

The hospital segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
SGLT2 Inhibitors Treatment Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying